{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'normal endothelial function, adenosine increases MBF by a factor of 2.5 or more while in', 'patients with endothelial dysfunction the increase is less than 2.0 (27).', 'Secondary endpoints:', 'The Seattle Angina Questionnaire (SAQ) (28) was used in pilot MVA studies. It is', 'currently used in clinical trials in MVA populations for ranolazine and thus provided a', 'basis for statistical calculations. The SAQ is a self-report instrument with 19 items', 'designed to quantify the physical and emotional effects of coronary artery disease. The', 'questionnaire has a 4-week recall period. It yields five dimensions, each scored separately:', 'physical limitation, angina stability, angina frequency, treatment satisfaction, and disease', 'perception. A SAQ-7 summary score can also be derived using 7 items from the physical', 'limitation, angina frequency and disease perception domains. The physical limitation', '(SAQ-PL) dimension is the most relevant for defining treatment benefit in this trial and', 'was thus specified as a secondary objective. The SAQ-PL dimension measures how', 'common daily activities representing low, medium, and high exertional requirements are', 'limited by angina (9 items). It is scored by assigning each response an ordinal value,', 'beginning with 1 for the response that implies the lowest level of functioning, and', 'summing across the 9 items. The score is then transformed to 0-100 range by subtracting', 'the lowest possible scale score, dividing by the range of the scale and multiplying by 100.', 'The possible range of scores is therefore 0 to 100, with higher scores better. A change of', '10 points is considered to be clinically important.', 'Safety will be assessed during the whole study on adverse events with a special focus on', 'BP, laboratory data and renal function.', 'Exploratory endpoints:', 'Assessment of angina episodes with or without short-acting nitrate intakes', 'Angina episodes and short-acting nitrate intakes collected by the patients in a diary will be', 'measured. This will allow assessing the number of angina episodes (and their severity).', 'Assessment of other dimensions of the SAQ and SAQ-7 score (29)', 'The SAQ yields five dimensions, each scored separately: physical limitation, angina stability,', 'angina frequency, treatment satisfaction, and disease perception. All the dimensions except', 'SAQ-PL will be assessed.', 'The SAQ-7 summary score can also be derived using 7 items from the physical limitation, angina', 'frequency and disease perception domains.', \"Assessment of patient's perceptions of treatment and symptoms\", \"The patient qualitative self-assessment aims to better understand the patient's views on their\", 'treatment and symptoms at baseline and at the end of the study. Three questions assessing the', \"patient's perception will be asked and a free-text box will be provided for patients to give\", 'qualitative answers. This assessment should take between 5-10 minutes, and the text will later be', 'Property of the Sanofi Group - strictly confidential', 'Page 34', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'analyzed using qualitative data analysis software to perform content analysis using text mining.', 'The patient will be asked to complete these three questions. The questions are:', 'Day 1 and at the end of treatment visit/permanent treatment discontinuation or Day 29:', '\"Please think back over the past week. In your own words, please describe the symptoms', 'you have experienced because of your angina without obstructive coronary artery', 'disease.', 'End of treatment visit/permanent treatment discontinuation or Day 29 only: \"Please think', 'about the study you have been part of. In your own words, please list the pros and cons of', 'study treatment\".', 'End of treatment visit/permanent treatment discontinuation or Day 29 only: \"Please give', 'your overall thoughts on the study treatment you have received as part of this study\".', 'Property of the Sanofi Group - strictly confidential', 'Page 35', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}